Theriva Biologics, Inc. (TOVX)

Theriva Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	6.22	6.7	7.78	7.57	6.47	5.03
Research & Development	10.36	12.03	14.31	11.72	7.8	5.13
Operating Expenses	16.58	18.73	22.09	19.29	14.27	10.16
Operating Income	-16.58	-18.73	-22.09	-19.29	-14.27	-10.16
Interest & Investment Income	0.35	0.7	1.44	0.51	0.01	0.04
Currency Exchange Gain (Loss)	0.03	-0	0	-0.04	-	-
EBT Excluding Unusual Items	-16.2	-18.04	-20.65	-18.82	-14.27	-10.12
Merger & Restructuring Charges	-	-	-	-0.2	-	-
Impairment of Goodwill	-	-5.59	-	-	-	-
Other Unusual Items	-9.99	-0.7	0.66	-2.09	-	-
Pretax Income	-26.19	-25.65	-19.99	-21.11	-14.27	-10.12
Income Tax Expense	-	-	-1.64	-1.43	-	-
Earnings From Continuing Operations	-26.19	-25.65	-18.35	-19.69	-14.27	-10.12
Minority Interest in Earnings	-	-	-	-	0	0.07
Net Income	-26.19	-25.65	-18.35	-19.69	-14.27	-10.04
Preferred Dividends & Other Adjustments	-	-	-	0.34	8.92	2.51
Net Income to Common	-26.19	-25.65	-18.35	-20.03	-23.19	-12.56
Shares Outstanding (Basic)	6	1	1	1	0	0
Shares Outstanding (Diluted)	6	1	1	1	0	0
Shares Change (YoY)	572.67%	109.24%	5.09%	25.76%	541.07%	15.65%
EPS (Basic)	-4.74	-19.03	-28.48	-32.66	-47.57	-165.13
EPS (Diluted)	-4.74	-19.03	-28.48	-32.66	-47.57	-165.13
Free Cash Flow	-18.51	-16.94	-19.2	-19.2	-12.9	-12.18
Free Cash Flow Per Share	-3.35	-12.56	-29.80	-31.31	-26.47	-160.13
EBITDA	-16.47	-18.59	-21.96	-19.21	-14.19	-9.96
D&A For EBITDA	0.11	0.14	0.14	0.09	0.09	0.2
EBIT	-16.58	-18.73	-22.09	-19.29	-14.27	-10.16

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q